Although the impact of IFN-β therapy on disease activity and its therapeutic efficiency is controversially discussed, IFN-β is the first-line treatment for patients with a relapsing-remitting MS [6,7,8]. Here, IFNB1 is linked to relapsing-remitting multiple sclerosis.